Daroudi Rajabali, Shafe Omid, Moosavi Jamal, Salimi Javad, Bayazidi Yahya, Zafarghandi Mohammad Reza, Maleki Majid, Moini Majid, Farshidmehr Pezhman, Sadeghipour Parham
Department of Health Economics and Management, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Vali-Asr Ave, 1995614331, Tehran, Iran.
Cost Eff Resour Alloc. 2021 May 13;19(1):29. doi: 10.1186/s12962-021-00283-7.
Screening program tend to recognized patients in their early stage and consequently improve health outcomes. Cost-effectiveness of the abdominal aortic aneurysm (AAA) screening program has been scarcely studied in developing countries. We sought to evaluate the cost-effectiveness of a screening program for the abdominal aortic aneurysm (AAA) in men aged over 65 years in Iran.
A Markov cohort model with 11 mutually exclusive health statuses was used to evaluate the cost-effectiveness of a population-based AAA screening program compared with a no-screening strategy. Transitions between the health statuses were simulated by using 3-month cycles. Data for disease transition probabilities and quality of life outcomes were obtained from published literature, and costs were calculated based on the price of medical services in Iran and the examination of the patients' medical records. The outcomes were life-years gained, the quality-adjusted life-year (QALY), costs, and the incremental cost-effectiveness ratio (ICER). The analysis was conducted for a lifetime horizon from the payer's perspective. Costs and effects were discounted at an annual rate of 3%. Uncertainty surrounding the model inputs was tested with deterministic and probabilistic sensitivity analyses.
The mean incremental cost of the AAA screening strategy compared with the no-screening strategy was $140 and the mean incremental QALY gain was 0.025 QALY, resulting in an ICER of $5566 ($14,656 PPP) per QALY gained. At a willingness-to-pay of 1 gross domestic product (GDP) per capita ($5628) per QALY gained, the probability of the cost-effectiveness of AAA screening was about 50%. However, at a willingness-to-pay of twice the GDP per capita per QALY gained, there was about a 95% probability for the AAA screening program to be cost-effective in Iran.
The results of this study showed that at a willingness-to-pay of 1 GDP per capita per QALY gained, a 1-time AAA screening program for men aged over 65 years could not be cost-effective. Nevertheless, at a willingness-to-pay of twice the GDP per capita per QALY gained, the AAA screening program could be cost-effective in Iran. Further, AAA screening in high-risk groups could be cost-effective at a willingness-to-pay of 1 GDP per capita per QALY gained.
筛查项目倾向于在疾病早期识别患者,从而改善健康结局。在发展中国家,腹主动脉瘤(AAA)筛查项目的成本效益鲜有研究。我们旨在评估伊朗65岁以上男性腹主动脉瘤(AAA)筛查项目的成本效益。
采用具有11种相互排斥健康状态的马尔可夫队列模型,评估基于人群的AAA筛查项目与不筛查策略相比的成本效益。健康状态之间的转换以3个月为周期进行模拟。疾病转换概率和生活质量结局的数据来自已发表的文献,成本根据伊朗医疗服务价格和患者病历检查计算得出。结局指标为获得的生命年、质量调整生命年(QALY)、成本和增量成本效益比(ICER)。从支付方的角度进行终身期分析。成本和效果以每年3%的贴现率进行贴现。通过确定性和概率敏感性分析检验模型输入的不确定性。
与不筛查策略相比,AAA筛查策略的平均增量成本为140美元,平均增量QALY增益为0.025 QALY,每获得1个QALY的ICER为5566美元(按购买力平价计算为14656美元)。在每获得1个QALY支付意愿为1个人均国内生产总值(GDP)(5628美元)的情况下,AAA筛查具有成本效益的概率约为50%。然而,在每获得1个QALY支付意愿为两倍人均GDP的情况下,AAA筛查项目在伊朗具有成本效益的概率约为95%。
本研究结果表明,在每获得1个QALY支付意愿为1个人均GDP的情况下,针对65岁以上男性的一次性AAA筛查项目不具有成本效益。然而,在每获得1个QALY支付意愿为两倍人均GDP的情况下,AAA筛查项目在伊朗可能具有成本效益。此外,在每获得1个QALY支付意愿为1个人均GDP的情况下,对高危人群进行AAA筛查可能具有成本效益。